Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME : Episode 10
Safety Profile of New Therapies
Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.
Video content above is prompted by the following:
- Based on the clinical trial data, how do you view the safety profiles of faricimab and aflibercept 8 mg?
- Does the long-term safety profile of aflibercept 2 mg increase your confidence in the safety of aflibercept 8 mg?
- Does the increased volume of aflibercept 8 mg raise concerns about the potential for elevated intraocular pressure? How do you evaluate and address this in clinical practice?
Recent Videos
Related Content
